By clicking “View Open Positions”, you acknowledge and consent to your personal information being transferred cross-border to Pivotal Headquarters in Hong Kong. For more details, please refer to the Recruitment Privacy Policy.
Karuna
THERAPEUTIC AREA
Schizophrenia and Alzheimer's disease psychosis
YEAR INVESTED
2019
STAGE
IPO'd in 2019; acquired by Bristol Myers Squibb
WEBSITE
Karuna Therapeutics is a clinical-stage company targeting muscarinic cholinergic receptors, a novel therapeutic modality for the treatment of psychosis and cognitive impairment across central nervous system disorders. Karuna’s lead candidate, KarXT, has demonstrated positive phase three data in schizophrenia.
SHANGHAI
Suite 2001, YI FUNG PLACE
99 West Ziyun Road
Changning District
Shanghai 200051, China
HONG KONG
17th Floor
AIRSIDE
2 Concorde Road, Kai Tak
Hong Kong SAR
SAN FRANCISCO
501 2nd Street, Suite 200
San Francisco, CA 94107
United States
中文
English
